Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (251-260 of 298) with videos related to

Pageof 30
Sort By:
The Journal of Allergy and Clinical Immunology|March 15, 2015
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trialJames G Krueger, Laura K Ferris, Alan Menter, et al.
Cutis|November 6, 2010
Optimizing topical therapies for treating psoriasis: a consensus conferenceJoshua A Zeichner, Mark G Lebwohl, Alan Menter, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.
The Journal of Dermatological Treatment|October 5, 2010
Improving clinical trial design in psoriasis: Perspectives from the global dermatology communityPeter van de Kerkhof, Jonathan Barker, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|September 30, 2014
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year resultsAlexa B Kimball, Kenneth J Rothman, Gregory Kricorian, et al.
JAMA Dermatology|April 6, 2013
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional studyAmy S Paller, Katherine Mercy, Mary J Kwasny, et al.
Journal of the American Academy of Dermatology|May 8, 2003
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksGerald D Weinstein, John Y M Koo, Gerald G Krueger, et al.
Journal of the American Academy of Dermatology|November 6, 2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)Bruce Strober, Melinda Gooderham, Elke M G J de Jong, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesAlice B Gottlieb, Robert E Kalb, Richard G Langley, et al.
Nature Genetics|November 11, 2003
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasisCynthia Helms, Li Cao, James G Krueger, et al.
Pageof 30

Showing results (251-260 of 298) with videos related to

Sort By:
Pageof 30
The Journal of Allergy and Clinical Immunology|March 15, 2015
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trialJames G Krueger, Laura K Ferris, Alan Menter, et al.
Cutis|November 6, 2010
Optimizing topical therapies for treating psoriasis: a consensus conferenceJoshua A Zeichner, Mark G Lebwohl, Alan Menter, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studiesMark Lebwohl, Alan Menter, Jonathan Weiss, et al.
The Journal of Dermatological Treatment|October 5, 2010
Improving clinical trial design in psoriasis: Perspectives from the global dermatology communityPeter van de Kerkhof, Jonathan Barker, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|September 30, 2014
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year resultsAlexa B Kimball, Kenneth J Rothman, Gregory Kricorian, et al.
JAMA Dermatology|April 6, 2013
Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional studyAmy S Paller, Katherine Mercy, Mary J Kwasny, et al.
Journal of the American Academy of Dermatology|May 8, 2003
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksGerald D Weinstein, John Y M Koo, Gerald G Krueger, et al.
Journal of the American Academy of Dermatology|November 6, 2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)Bruce Strober, Melinda Gooderham, Elke M G J de Jong, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesAlice B Gottlieb, Robert E Kalb, Richard G Langley, et al.
Nature Genetics|November 11, 2003
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasisCynthia Helms, Li Cao, James G Krueger, et al.
Pageof 30